Aelis Farma SA

Paris Stock Exchange AELIS.PA

Aelis Farma SA Total Non-Current Liabilities for the year ending December 31, 2023: USD 3.36 M

Aelis Farma SA Total Non-Current Liabilities is USD 3.36 M for the year ending December 31, 2023, a -13.85% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Aelis Farma SA Total Non-Current Liabilities for the year ending December 31, 2022 was USD 3.91 M, a -74.01% change year over year.
  • Aelis Farma SA Total Non-Current Liabilities for the year ending December 31, 2021 was USD 15.03 M, a 101.01% change year over year.
  • Aelis Farma SA Total Non-Current Liabilities for the year ending December 31, 2020 was USD 7.47 M, a 40.85% change year over year.
  • Aelis Farma SA Total Non-Current Liabilities for the year ending December 31, 2019 was USD 5.31 M, a 108.59% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
SV Wall Street
Paris Stock Exchange: AELIS.PA

Aelis Farma SA

CEO Dr. Pier Vincenzo Piazza M.D., Ph.D.
IPO Date Feb. 18, 2022
Location France
Headquarters 146 rue Léo Saignat
Employees 26
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Tobacco Vaccines
Description

Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.

StockViz Staff

February 7, 2025

Any question? Send us an email